1. 1) Koyanagi K., Kubota T., Kobayashi D., Kihara T., Yoshida T., Miisho T., Saito Y., Uchigoshi H., Takaki J., Seo T., Shimazoe T., Yakugaku Zasshi, 133, 1215–1221 (2013).
2. 2) MERCK MANUAL, “Nonadherence in Children.”: ‹https://www.merckmanuals.com/professional/pediatrics/principles-of-drug-treatment-in-children/nonadherence-in-children›, cited 25 May 2019.
3. 3) Blume J., Ruano A., Wang S., Jacson D., Tylleskar T., Strand L., BMC Pediatr., 18, 117 (2018).
4. 4) Committee for Medicinal Products for Human Use (CHMP) Paediatric Committee (PDCO) European Medicines Agency. “Guideline on pharmaceutical development of medicines for paediatric use. EMA/CHMP/QWP/805880/2012Rev.2,2013.”: ‹http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf›, cited 1 August, 2019.
5. 5) Hiraiwa S., Obayashi M., Kougo T., Yamano H., Saeki T., Anjyo S., The Journal of Pediatric Practice, 67, 1342–1346 (2004).